Exelixis | EXEL - Cash And Equivalent


Exelixis reported $226.15M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bayer EUR 5.73B 943M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
Eisai JPY 245.42B 56.22B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Exelixis USD 226.15M 256.34M Mar/2026
Genmab DKK 1.72B 46M Dec/2025
Glaxosmithkline GBP 3.44B 146M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Moderna USD 1.72B 185M Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Pfizer USD 976M 727M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sanofi EUR 5.54B 2.11B Mar/2026
Takeda JPY 460.98B 134.07B Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Xencor USD 44.66M 30.49M Jun/2026